Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders

Douglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto, Patrick J. Waters, Frederico M. De Haidar Jorge, Toshiyuki Takahashi, Ichiro Nakashima, Samira Luisa Apostolos- Pereira, Natalia Talim Renata Faria Simm, Angelina Maria Martins Lino, Tatsuro Misu, Maria Isabel Leite, Masashi Aoki, Kazuo Fujihara

Research output: Contribution to journalArticle

445 Citations (Scopus)

Abstract

Objective: To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies. Methods: Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested forMOG and AQP4 antibodies using cell-based assays with live transfected cells. Results: Among the 215 patients with NMOSD, 7.4% (16/215) were positive for MOG antibodies and 64.7% (139/215)were positive for AQP4 antibodies. No patientswere positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) of the patients negative for AQP4 antibodies. Compared with patients with AQP4 antibodies or patients who were seronegative, patients with MOG antibodies were more frequently male, had a more restricted phenotype (optic nerve more than spinal cord), more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had spinal cord lesions distributed in the lower portion of the spinal cord, and usually demonstrated better functional recovery after an attack. Conclusions: Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.

Original languageEnglish
Pages (from-to)474-481
Number of pages8
JournalNeurology
Volume82
Issue number6
DOIs
Publication statusPublished - 2014 Feb 11

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders'. Together they form a unique fingerprint.

  • Cite this

    Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., De Haidar Jorge, F. M., Takahashi, T., Nakashima, I., Apostolos- Pereira, S. L., Simm, N. T. R. F., Lino, A. M. M., Misu, T., Leite, M. I., Aoki, M., & Fujihara, K. (2014). Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders. Neurology, 82(6), 474-481. https://doi.org/10.1212/WNL.0000000000000101